S Rahman1,2, C M Pierce Campbell3, B N Torres4, M T O'Keefe5, D J Ingles6, L L Villa7, R J Carvalho da Silva8, R C Cintra9, E Lazcano-Ponce10, J Salmeron10,11, M Quiterio10, A R Giuliano2. 1. Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA. 2. Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 3. Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. christine.piercecampbell@moffitt.org. 4. Department of Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 5. Department of Performance Improvement, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 6. Vanderbilt Institute for Global Health, Nashville, TN, USA. 7. Department of Radiology & Oncology, School of Medicine, University of São Paulo, São Paulo, Brazil. 8. Centro de Referencia e Treinamento em DST/Aids, São Paulo, Brazil. 9. Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil. 10. Instituto Nacional de Salúd Publica, Cuernavaca, Mexico. 11. Instituto Mexicano del Seguro Social, Cuernavaca, Mexico.
Abstract
OBJECTIVES: This cross-sectional study examined the distribution and correlates of salivary secretory leukocyte protease inhibitor (SLPI) concentrations within a multinational cohort of men. METHODS: Extracellular SLPI was measured in oral gargle cell supernatants of 378 men from three countries using an ELISA-based assay. Risk factor data were collected by a questionnaire. Factors associated with SLPI were assessed using linear and logistic regression for continuous and categorical SLPI, respectively. RESULTS: Among men aged 18-73 years, the median SLPI concentration was 492.0 ng ml-1 (range: 2.3-1919.9). In multivariable modeling, men in Brazil and younger men (18-30 years) were more likely to have higher levels of SLPI [adjusted odds ratio (aOR) 3.84; 95% confidence interval (CI): 1.94-7.59, and aOR 3.84; 95% CI: 1.98-7.43, respectively]. Men with a self-reported sexually transmitted diseases diagnosis in the past 6 months were more likely to have higher SLPI levels (aOR 2.98; 95% CI: 1.1-7.83) and men reporting bleeding/swollen gums were less likely to have higher SLPI (aOR 0.34; 95% CI: 0.15-0.79). Similar results were observed for linear regression models. CONCLUSIONS: Secretory leukocyte protease inhibitor concentrations varied significantly by country and decreased with increasing age. The interaction between SLPI, modifiable factors, and oral infections that influence cancer risk warrants further investigation.
OBJECTIVES: This cross-sectional study examined the distribution and correlates of salivary secretory leukocyte protease inhibitor (SLPI) concentrations within a multinational cohort of men. METHODS: Extracellular SLPI was measured in oral gargle cell supernatants of 378 men from three countries using an ELISA-based assay. Risk factor data were collected by a questionnaire. Factors associated with SLPI were assessed using linear and logistic regression for continuous and categorical SLPI, respectively. RESULTS: Among men aged 18-73 years, the median SLPI concentration was 492.0 ng ml-1 (range: 2.3-1919.9). In multivariable modeling, men in Brazil and younger men (18-30 years) were more likely to have higher levels of SLPI [adjusted odds ratio (aOR) 3.84; 95% confidence interval (CI): 1.94-7.59, and aOR 3.84; 95% CI: 1.98-7.43, respectively]. Men with a self-reported sexually transmitted diseases diagnosis in the past 6 months were more likely to have higher SLPI levels (aOR 2.98; 95% CI: 1.1-7.83) and men reporting bleeding/swollen gums were less likely to have higher SLPI (aOR 0.34; 95% CI: 0.15-0.79). Similar results were observed for linear regression models. CONCLUSIONS:Secretory leukocyte protease inhibitor concentrations varied significantly by country and decreased with increasing age. The interaction between SLPI, modifiable factors, and oral infections that influence cancer risk warrants further investigation.
Authors: Christian Cordes; Robert Häsler; Christian Werner; Tibor Görögh; Christoph Röcken; Lena Hebebrand; W Martin Kast; Markus Hoffmann; Stefan Schreiber; Petra Ambrosch Journal: Int J Oncol Date: 2011-04-14 Impact factor: 5.650
Authors: Amit Chattopadhyay; Laurie R Gray; Lauren L Patton; Daniel J Caplan; Gary D Slade; Hsaio-Chuan Tien; Diane C Shugars Journal: Infect Immun Date: 2004-04 Impact factor: 3.441
Authors: Markus Hoffmann; Elgar S Quabius; Silke Tribius; Lena Hebebrand; Tibor Görögh; Gordana Halec; Tomas Kahn; Jürgen Hedderich; Christoph Röcken; Jochen Haag; Tim Waterboer; Markus Schmitt; Anna R Giuliano; W Martin Kast Journal: Oncol Rep Date: 2013-03-05 Impact factor: 3.906